Dr. William Harris, professor at the Sanford School of Medicine and co-inventor of the Omega-3 Index, established that a blood omega-3 level above 8% correlates with a 35% reduction in cardiovascular mortality — comparable to the benefit of statin therapy. A 2020 Mayo Clinic Proceedings meta-analysis (40 RCTs, n=135,267) confirmed a 13% reduction in heart attack risk with EPA+DHA supplementation above 1g/day. Omega-3 fatty acids, specifically EPA and DHA, are among the most studied supplements in clinical medicine. The evidence file is enormous: thousands of trials, hundreds of meta-analyses, and clinical guidelines from every major cardiology organization.
The REDUCE-IT trial, led by Dr. Deepak Bhatt at Brigham and Women's Hospital (n=8,179, published in NEJM 2019), demonstrated that high-dose icosapent ethyl (4 grams/day of pure EPA) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides.
For triglyceride reduction, omega-3s at therapeutic doses (2-4 grams EPA+DHA daily) produce 15-30% reductions. Standard dietary supplement doses (500-1000 mg) are insufficient for meaningful triglyceride reduction.
Brain health evidence is accumulating. DHA comprises roughly 40% of polyunsaturated fatty acids in the brain. Dr. Yves Bherer, a neuropsychologist at the University of Montreal, and Dr. Martha Clare Morris at Rush University (author of the MIND diet) have independently demonstrated that higher omega-3 intake associates with lower rates of cognitive decline — Morris's Rush Memory and Aging Project (n=923, 4.5-year follow-up) found that one fish meal per week reduced Alzheimer's risk by 60%. Interventional trials have shown mixed results, suggesting prevention rather than reversal.
Inflammation modulation is mechanistically well-understood. Dr. Charles Serhan, professor of anesthesia at Harvard Medical School and Brigham and Women's Hospital, discovered specialized pro-resolving mediators (SPMs) — resolvins, protectins, and maresins — produced from EPA and DHA that actively resolve inflammation rather than merely suppressing it. This discovery shifted the field from viewing omega-3s as passive anti-inflammatory agents to recognizing them as precursors of active resolution pathways.
Dosing: for general health, 500-1000 mg combined EPA+DHA daily. For cardiovascular risk reduction, 2-4 grams daily under medical supervision. Dr. Harris recommends an Omega-3 Index test (target: above 8%) to guide individual dosing. Third-party testing (IFOS, USP, NSF) is important for quality assurance.